← Browse by Condition
Medical Condition

advanced tumors

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced tumors Clinical Trials

How many clinical trials are currently recruiting for advanced tumors?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for advanced tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced tumors?
advanced tumors research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced tumors clinical trial?
Eligibility criteria for advanced tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Shanghai Institute Of Biological Products 1 trial
Advenchen Laboratories Nanjing Ltd. 1 trial
The University of Hong Kong-Shenzhen Hospital 1 trial
Jonsson Comprehensive Cancer Center 1 trial

Recruiting Clinical Trials

NCT07205198 Phase 1
Recruiting

A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.

Enrollment
160 pts
Location
China
Sponsor
Shanghai Institute Of Biologic...
View Trial →
NCT07179081 Phase 1
Recruiting

A Study of AL58805 in Patients With Advanced Tumors

Enrollment
40 pts
Location
China
Sponsor
Advenchen Laboratories Nanjing...
View Trial →
NCT06314087 Phase 2
Recruiting

Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)

Enrollment
154 pts
Location
China
Sponsor
The University of Hong Kong-Sh...
View Trial →
NCT06788938 Phase 2
Recruiting

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Enrollment
29 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology